Positive News SentimentPositive NewsNASDAQ:AVTE Aerovate Therapeutics (AVTE) Stock Price, News & Analysis $7.09 -0.16 (-2.21%) As of 05/29/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aerovate Therapeutics Stock (NASDAQ:AVTE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aerovate Therapeutics alerts:Sign Up Key Stats Today's Range$6.99▼$7.6350-Day Range$2.68▼$96.9552-Week Range$43.75▼$884.98Volume372,015 shsAverage Volume18,821 shsMarket Capitalization$205.50 millionP/E RatioN/ADividend YieldN/APrice Target$78.75Consensus RatingHold Company OverviewAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Read More… Aerovate Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreAVTE MarketRank™: Aerovate Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 805th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingAerovate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageAerovate Therapeutics has received no research coverage in the past 90 days.Read more about Aerovate Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aerovate Therapeutics are expected to grow in the coming year, from ($2.64) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aerovate Therapeutics is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aerovate Therapeutics is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAerovate Therapeutics has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Aerovate Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for AVTE. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAerovate Therapeutics does not currently pay a dividend.Dividend GrowthAerovate Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for AVTE. News and Social Media2.7 / 5News SentimentN/A News SentimentAerovate Therapeutics has a news sentiment score of 1.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Aerovate Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for AVTE on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aerovate Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.90% of the stock of Aerovate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Aerovate Therapeutics' insider trading history. Receive AVTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AVTE Stock News HeadlinesJade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 MillionApril 28, 2025 | globenewswire.comAerovate Stockholders Approve Merger Proposal With Jade BiosciencesApril 23, 2025 | nasdaq.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.May 31, 2025 | American Alternative (Ad)Aerovate Therapeutics stockholders approve proposed merger with Jade BiosciencesApril 23, 2025 | markets.businessinsider.comAerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related ProposalsApril 21, 2025 | prnewswire.comAerovate Therapeutics declares special cash dividend, estimated $2.40 per shareApril 10, 2025 | markets.businessinsider.comAerovate Therapeutics sees $67.6M-$69.6M dividend in connection with JadeApril 9, 2025 | markets.businessinsider.comAerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade BiosciencesApril 9, 2025 | prnewswire.comSee More Headlines AVTE Stock Analysis - Frequently Asked Questions How have AVTE shares performed this year? Aerovate Therapeutics' stock was trading at $92.75 on January 1st, 2025. Since then, AVTE shares have decreased by 92.4% and is now trading at $7.09. View the best growth stocks for 2025 here. How were Aerovate Therapeutics' earnings last quarter? Aerovate Therapeutics, Inc. (NASDAQ:AVTE) issued its quarterly earnings results on Friday, April, 25th. The company reported ($3.15) EPS for the quarter, beating the consensus estimate of ($10.50) by $7.35. When did Aerovate Therapeutics' stock split? Aerovate Therapeutics shares reverse split on the morning of Tuesday, April 29th 2025. A 1-35 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 28th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Aerovate Therapeutics IPO? Aerovate Therapeutics (AVTE) raised $100 million in an initial public offering (IPO) on Wednesday, June 30th 2021. The company issued 7,150,000 shares at $13.00-$15.00 per share. Who are Aerovate Therapeutics' major shareholders? Top institutional investors of Aerovate Therapeutics include ADAR1 Capital Management LLC (5.04%), Allostery Investments LP (4.90%), Deltec Asset Management LLC (1.25%) and Goldman Sachs Group Inc. (1.22%). Insiders that own company stock include David S Grayzel, Hunter Gillies, George A Eldridge, Ralph Niven, Benjamin T Dake, Timothy P Noyes and Marinus Verwijs. View institutional ownership trends. How do I buy shares of Aerovate Therapeutics? Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aerovate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aerovate Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Palo Alto Networks (PANW), Tesla (TSLA) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings4/25/2025Record date for 4/28 Dividend4/25/2025Dividend Payable4/28/2025Ex-Dividend for 4/28 Dividend4/29/2025Today5/30/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVTE CIK1798749 Webaerovatetx.com Phone617-443-2400FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$78.75 High Stock Price Target$105.00 Low Stock Price Target$70.00 Potential Upside/Downside+1,010.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$75.52 million Net MarginsN/A Pretax MarginN/A Return on Equity-90.19% Return on Assets-77.47% Debt Debt-to-Equity RatioN/A Current Ratio8.78 Quick Ratio8.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.96 per share Price / Book1.79Miscellaneous Outstanding Shares28,985,000Free Float21,685,000Market Cap$205.50 million OptionableOptionable Beta0.95 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:AVTE) was last updated on 5/31/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.